Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT02300766
Recruiting Observational

Cerebellar Mutism Syndrome Study

NCT02300766 · tracked via the Priya Life Science Denmark tracker
Sponsor
Copenhagen University Hospital, Rigshospitalet
Phase
Observational
Started
2014-10
Last updated
2026-08-12

Condition(s) studied

Infratentorial NeoplasmsMutism

Study summary

The purpose of this study is to determine why up to 25% of the pediatric patients who have surgery for a tumor in the posterior fossa develops the Cerebellar Mutism Syndrome (CMS). Furthermore the purpose is to explore the clinical course and the best treatment of the syndrome.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Age \< 18 years at the date of first imaging showing this tumour * Tumour in the cerebellum/4th ventricle/brainstem with intention to treat with surgical resection or open biopsy. Second and further surgeries are also included. * Informed consent from custodial parent(s) Exclusion Criteria: * None

Primary outcome measure(s)

  • Development and progress of Cerebellar Mutism Syndrome — 1 year after surgery
    The development of CMS is determined by a survey developed Robertson et al. The correlation between the risk of developing CMS and different neurosurgical techniques, genomic variants, treatments, tumor types, comorbidities, neuroradiologic findings, handedness and preoperative language status will be explored.

Trial sites (32)

FacilityCityRegionStatus
Medical University of Vienna Vienna Austria Recruiting
University Hospital Leuven Leuven Belgium Recruiting
Motol University Hospital Prague Czechia Recruiting
Aalborg University Hospital Aalborg Denmark Recruiting
Aarhus University Hospital Aarhus Denmark Recruiting
Rigshospitalet Copenhagen Denmark Recruiting
Odense University Hospital Odense Denmark Recruiting
Helsinki University Central Hospital Helsinki Finland Recruiting
Kuopio University Hospital Kuopio Finland Not Yet Recruiting
Oulu University Hospital Oulu Finland Not Yet Recruiting
Tampere University Hospital Tampere Finland Not Yet Recruiting
Turku University Hospital Turku Finland Not Yet Recruiting
University of Leipzig Medical Center Leipzig Germany Recruiting
Universitätsklinikum Tübingen Tübingen Germany Recruiting
Semmelweis University, 2nd Dept of Pediatrics Budapest Hungary Recruiting
Ospedale Pediatrico Bambino Gesù Rome Rome Recruiting
Hospital of Lithuanian University of Health Sciences Kauno klinikos Kaunas Lithuania Recruiting
Radboud University Nijmegen Medical Centre Nijmegen Gelderland Recruiting
UMC Groningen Groningen Netherlands Active Not Recruiting
UMC Utrecht Utrecht Netherlands Recruiting
Haukeland University Hospital Bergen Norway Recruiting
Oslo University Hospital Oslo Norway Not Yet Recruiting
University Hospital of North Norway Tromsø Norway Not Yet Recruiting
St. Olav's Hospital Trondheim Norway Recruiting
Sant Joan de Déu Barcelona Hospital Barcelona Spain Recruiting
Sahlgrenska University Hospital Gothenburg Sweden Recruiting
Linköping University Hospital Linköping Sweden Recruiting
Skåne University Hospital Skåne Sweden Recruiting
Karolinska University Hospital Stockholm Sweden Recruiting
University Hospital of Umeå Umeå Sweden Recruiting
Uppsala University Hospital Uppsala Sweden Recruiting
Alder Hey Childrens NHS Foundation Trust Liverpool United Kingdom Recruiting

More Copenhagen University Hospital, Rigshospitalet trials in Denmark

Effect of Large Neutral Amino Acids in Adults With Classical Phenylketonuria Recruiting
Immediate Versus Postponed Single Blastocyst Transfer in mNC-FET Active, not recruiting
The Copenhagen Gender Identity Cohort Recruiting
Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection Recruiting
Precision Medicine in the Depression Treatment Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02300766 on ClinicalTrials.gov ↗ ← All trials in Denmark